CHEMICON INTERNATIONAL, INC. – Trademark Portfolio
Entity Type: 03
CHEMICON INTERNATIONAL, INC. holds 24 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 22 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include ESGRO, TRAPEZE, CHEMICON, HYBRISOL, and AMPLIFLUOR. The owner is based in TEMECULA, CA.
28820 SINGLE OAK DRIVE
TEMECULA, CA 92590
Showing of trademarks Trademarks
Trademark Classifications
CHEMICON INTERNATIONAL, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CHEMICON INTERNATIONAL, INC. have?
CHEMICON INTERNATIONAL, INC. has 24 U.S. trademarks filed with the USPTO. Of these, 6 registered, 3 abandoned, 15 cancelled.
What trademark classes does CHEMICON INTERNATIONAL, INC. file in?
CHEMICON INTERNATIONAL, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are CHEMICON INTERNATIONAL, INC.'s most well-known trademarks?
CHEMICON INTERNATIONAL, INC.'s registered trademark portfolio includes well-known marks such as ESGRO, TRAPEZE, CHEMICON, HYBRISOL, and AMPLIFLUOR. These are among 6 currently registered trademarks in the portfolio.
What is CHEMICON INTERNATIONAL, INC.'s trademark registration success rate?
CHEMICON INTERNATIONAL, INC. has a 25% trademark registration rate, with 6 out of 24 resolved applications resulting in successful registration. Currently, 0 applications are pending review.